The Congressional Budget Office believes the president's proposal to eliminate low-income beneficiaries' cost sharing for generic drugs would cost more than $18 billion dollars over 10 years, despite the fact that the White House Office of Management and Budget previously said the proposal would be nearly budget neutral. Despite this discrepancy, which caught budget watchers’ eyes, CBO stayed mum on the impacts of a number of other hotly debated drug-pricing ideas in the president’s budget -- like moving certain drugs...